Maintenance Intermittent Therapy for Symptomatic GERD Patients
NCT00165841
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG:
Rabeprazole 20 mg
Sponsor
Eisai Inc.